Search
Metocurine
go.drugbank.com/drugs/DB01336ApprovedPatients on chronic anticonvulsant drugs are relatively resistant to metocurine. [A2393] … Dimethyltubocurarinium (INN) or metocurine (USAN), also known as dimethyltubocurarine, is a non-depolarizing muscle relaxant.
Synonyms: O,O-DimethylchondrocurarineVernakalant
go.drugbank.com/drugs/DB06217ApprovedInvestigationalVernakalant was developed by Cardiome Pharma as as an antiarrhythmic drug intended for rapid conversion of atrial fibrillation to sinus rhythm. … It is an investigational drug under regulatory review by FDA.
Suvorexant
go.drugbank.com/drugs/DB09034ApprovedInvestigationalSuvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia.
Carbazochrome
go.drugbank.com/drugs/DB09012ApprovedWithdrawnIt is not FDA-approved but is available as tablets or IM/SC injections in the treatment of hemorrhages in a number of countries. … In the future this may prevent excessive blood flow during surgical operations and the treatment of hemorrhoids, but research on effectiveness and severity of side effects remains inconclusive.
International brands: Na Neng, Le Zhi NaEslicarbazepine acetate
go.drugbank.com/drugs/DB09119ApprovedInvestigationalEslicarbazepine's mechanism of action is not well understood, but it is known that it does exert anticonvulsant activity by inhibiting repeated neuronal firing and stabilizing the inactivated state of … Eslicarbazepine acetate (ESL) is an anticonvulsant medication approved for use in Europe, the United States and Canada as an adjunctive therapy for partial-onset seizures that are not adequately controlled
Triflusal
go.drugbank.com/drugs/DB08814ApprovedWithdrawnTriflusal is a 2-acetoxy-4-trifluoromethylbenzoic acid and it is an aspirin chemically-related molecule but not a derivative. … Uriach and Company and even though it is commercialized in different countries it is not approved by the FDA, EMA or HealthCanada.
Gilteritinib
go.drugbank.com/drugs/DB12141ApprovedInvestigational[A40044] Gilteritinib was developed by Astellas Pharma and FDA approved on November 28, 2018. … [A40036] It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression observed in other therapies.
Lasmiditan
go.drugbank.com/drugs/DB11732ApprovedInvestigational[L9338,L9356] It was also approved by the European Commission on August 17, 2022.[L43997] Traditionally, the triptan class of anti-migraine medications (e.g. … [A187316,A187322] Lasmiditan, in contrast, is a highly selective agonist of 5-HT<sub>1F</sub> receptors, carrying virtually no affinity for other receptors which appear to be largely responsible for
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeCrizanlizumab
go.drugbank.com/drugs/DB15271ApprovedInvestigationalIt was developed by Novartis and was granted FDA approval on November 15, 2019. … [A187904] Though hydroxyurea has been shown to reduce the frequency of vaso-occlusive crises, adherence to this therapy is difficult due to adverse effects and the high variability of response to the drug
Colesevelam
go.drugbank.com/drugs/DB00930ApprovedInvestigationalIt works by binding bile acids in the intestine. Bile acids are made when cholesterol is broken down in the body. Removing these bile acids helps to lower blood cholesterol. … Colesevelam is used with exercise and diet changes (restriction of cholesterol and fat intake) to reduce the amount of cholesterol and certain fatty substances in the blood.
Categories: Non-statin Hypolipidemic Agents Indicated for Hyperlipidemia